HLN Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
NYSE · Pharmaceuticals · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Mar 13, 2026HLN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
HLN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About Haleon plc American Depositary Shares (Each representing two Ordinary Shares) Company overview from Wikipedia
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022.
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange.
History
GSK and Pfizer merged their consumer healthcare businesses in 2019. GSK owned just over two thirds of the joint venture, and Pfizer owned the remainder. Annual sales were around £10 billion across 120 markets in 2020. GSK then announced plans to spin off Haleon in 2022 to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division," according to Reuters. Unilever offered £50 billion for the business in 2022, which GSK rejected. Nestlé examined the possibility of a bid in conjunction with Reckitt. In October 2023, GSK reduced its ownership in Haleon to 7.4%, and in January 2024 it further reduced its ownership to 4.2%.
In August 2023, Haleon sold its Lamisil antifungal brand to Karo Healthcare AB for £235 million, and in February 2024, Haleon sold its ChapStick lip care brand to Yellow Wood Partners for £401 million.
In March 2024, Pfizer reduced its share in Haleon from 32% to 24% per cent by selling 630 million shares in a public offering.
Further sales followed: in April 2024, Haleon announced that it would close its Sensodyne toothpaste factory in Maidenhead, moving that manufacturing to Slovakia, and it outsourced mouthwash manufacturing to an unrelated company and, in September 2024, the company completed the sale of its non-US nicotine replacement therapy business to Dr. Reddy's Laboratories in a deal worth £458 million.
In March 2025, Pfizer sold its entire stake in Haleon for £2.5 billion ($3.24 billion), exiting the consumer healthcare business it helped create by its 2019 joint venture with GSK.
Operations
Oral health accounted for 28.5 percent of revenue in 2021.
Sir Dave Lewis is chairman, with Brian McNamara as chief executive.
Brands
Current
Brands include:
=== Divested ===
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | HLN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E | 54.65Y avg ≈64.5 | ≈64.5 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | HLN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Gross Margin | 64.2%5Y avg ≈61.3% | ≈61.3% | · | · | |
| Operating Margin | 21.9%5Y avg ≈19.0% | ≈19.0% | · | · | |
| EBITDA Margin | 25.1%5Y avg ≈19.8% | ≈19.8% | · | · | |
| Pretax Margin | 19.5%5Y avg ≈16.5% | ≈16.5% | · | · | |
| Net Profit Margin | 15.1%5Y avg ≈11.7% | ≈11.7% | · | · | |
| ROA | 5.0%5Y avg ≈3.8% | ≈3.8% | · | · | |
| ROE | 10.2%5Y avg ≈7.6% | ≈7.6% | · | · | |
| ROIC | 11.5%5Y avg ≈9.5% | ≈9.5% | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | HLN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio | 0.95Y avg ≈1.0 | ≈1.0 | · | · | |
| Quick Ratio | 0.75Y avg ≈0.7 | ≈0.7 | · | · | |
| Interest Coverage | 7.15Y avg ≈6.2 | ≈6.2 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | HLN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.35Y avg ≈0.3 | ≈0.3 | · | · | |
| Inventory Turnover | 3.65Y avg ≈3.5 | ≈3.5 | · | · | |
| Receivables Turnover | 5.45Y avg ≈5.6 | ≈5.6 | · | · | |
| Revenue / Employee | ≈$449.6K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Aug 14, 2026 | $0.06 | USD | ≈2.0% |
| Apr 10, 2026 | $0.13 | USD | ≈1.9% |
| Aug 15, 2025 | $0.06 | USD | ≈1.8% |
| Apr 25, 2025 | $0.12 | USD | ≈1.7% |
| Aug 16, 2024 | $0.05 | USD | ≈1.6% |
| Mar 14, 2024 | $0.11 | USD | ≈1.8% |
| Aug 24, 2023 | $0.05 | USD | ≈1.3% |
| Mar 16, 2023 | $0.06 | USD | ≈0.73% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| Dec. 31, 2024 | $0.04 | $0.04 | 7.2% | |
| Sept. 30, 2024 | $0.05 | $0.05 | -1.9% | |
| June 30, 2024 | $0.04 | $0.04 | 2.3% | |
| March 31, 2024 | $0.05 | $0.05 | 7.6% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $11.03B | $11.23B | $11.30B | $10.86B | $9.54B | |
| Cost of Revenue | $3.95B | $4.41B | $4.55B | $4.28B | $3.60B | |
| Gross Profit | $7.08B | $6.82B | $6.75B | $6.58B | $5.95B | |
| R&D Expense | $316M | $298M | $311M | $300M | $257M | |
| SG&A Expense | $4.36B | $4.45B | $4.41B | $4.48B | $4.09B | |
| Operating Income | $2.41B | $2.21B | $2.00B | $1.82B | $1.64B | |
| Interest Expense | $340M | $384M | $402M | $258M | $19M | |
| Interest Income | $78M | $82M | $34M | $51M | $17M | |
| Pretax Income | $2.15B | $1.91B | $1.63B | $1.62B | $1.64B | |
| Income Tax | $472M | $435M | $517M | $499M | $197M | |
| Net Income | $1.67B | $1.44B | $1.05B | $1.06B | $1.39B | |
| EPS (Basic) | $0.19 | $0.16 | $0.11 | $0.12 | $0.15 | |
| EPS (Diluted) | $0.18 | $0.16 | $0.11 | $0.12 | $0.15 | |
| Shares (Basic) | 8,982,000,000 | 9,132,000,000 | 9,233,000,000 | 9,235,000,000 | 9,234,573,831 | |
| Shares (Diluted) | 9,026,000,000 | 9,175,000,000 | 9,263,000,000 | 9,239,000,000 | 9,235,000,000 | |
| EBITDA | $2.77B | $2.21B | $2.00B | $1.82B | · |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.32B | $2.25B | $1.04B | $684M | $414M | |
| Receivables | $2.06B | $2.06B | $1.86B | $1.88B | $2.21B | |
| Inventory | $1.02B | $1.19B | $1.41B | $1.35B | $951M | |
| Current Assets | $4.55B | $5.72B | $4.82B | $4.06B | $5.25B | |
| PP&E (Net) | $1.87B | $1.81B | $1.78B | $1.76B | $1.56B | |
| Goodwill | $8.13B | $8.20B | $8.32B | $8.40B | $8.25B | |
| Total Assets | $32.63B | $34.31B | $34.05B | $34.81B | $34.45B | |
| Accounts Payable | $3.73B | $3.71B | $3.53B | $3.62B | $3.00B | |
| Current Liabilities | $4.93B | $5.81B | $4.64B | $4.37B | $4.24B | |
| Total Liabilities | $16.15B | $18.09B | $17.33B | $18.36B | $7.97B | |
| Retained Earnings | $27.85B | $27.27B | $27.47B | $26.73B | $37.54B | |
| Stockholders' Equity | $16.43B | $16.17B | $16.61B | $16.33B | $26.36B |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| D&A | $360M | $324M | $309M | · | · | |
| Other Non-cash | $607M | · | · | · | · | |
| Operating Cash Flow | $2.63B | $2.30B | $2.10B | $2.06B | $1.36B | |
| CapEx | $322M | $250M | $234M | $304M | $228M | |
| Investing Cash Flow | $-346M | $528M | $-134M | $-8.78B | $-33M | |
| Financing Cash Flow | $-3.14B | $-1.54B | $-1.57B | $6.91B | $-1.24B | |
| Free Cash Flow | $2.31B | $2.05B | $1.87B | $1.76B | · | |
| Levered FCF | $2.05B | $1.75B | $1.59B | $1.58B | · |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 64.2% | 60.8% | 59.7% | 60.6% | · | |
| Operating Margin | 21.9% | 19.6% | 17.7% | 16.8% | · | |
| Net Margin | 15.1% | 12.8% | 9.3% | 9.8% | · | |
| Pretax Margin | 19.5% | 17.0% | 14.4% | 14.9% | · | |
| EBITDA Margin | 25.1% | 19.6% | 17.7% | 16.8% | · | |
| ROA | 5.0% | 4.2% | 3.0% | 3.1% | · | |
| ROE | 10.2% | 8.8% | 6.4% | 5.0% | · | |
| ROIC | 11.5% | 10.5% | 8.2% | 7.7% | · |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 1.0 | 1.0 | 0.9 | · | |
| Quick Ratio | 0.7 | 0.7 | 0.6 | 0.6 | · | |
| Interest Coverage | 7.1 | 5.7 | 5.0 | 7.1 | · |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | 0.3 | 0.3 | · | |
| Inventory Turnover | 3.6 | 3.4 | 3.3 | 3.7 | · | |
| Receivables Turnover | 5.4 | 5.7 | 6.0 | 5.3 | · |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue / Share | $1.22 | $1.22 | $1.22 | $1.18 | · | |
| Cash Flow / Share | $0.29 | $0.25 | $0.23 | $0.22 | · | |
| EPS (TTM) | $0.18 | $0.16 | $0.11 | $0.12 | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue TTM | $11.03B | $11.23B | $11.30B | $10.86B | · | |
| Net Income TTM | $1.67B | $1.44B | $1.05B | $1.06B | · | |
| P/E | 54.6 | 60.8 | 72.8 | 69.6 | · | |
| Earnings Yield | 1.8% | 1.7% | 1.4% | 1.4% | · |
Per Share
| Metric | Trend | Q4 2023 |
|---|---|---|
| EPS (TTM) | $0.11 |
Valuation (TTM)
| Metric | Trend | Q4 2023 |
|---|---|---|
| Revenue TTM | $11.30B | |
| Net Income TTM | $1.05B | |
| P/E | 72.8 | |
| Earnings Yield | 1.4% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $11.03B | $11.23B | $11.30B | $10.86B | $9.54B |
| Gross Margin % | 64.2% | 60.8% | 59.7% | 60.6% | · |
| Operating Margin % | 21.9% | 19.6% | 17.7% | 16.8% | · |
| Net Income | $1.67B | $1.44B | $1.05B | $1.06B | $1.39B |
| Diluted EPS | $0.18 | $0.16 | $0.11 | $0.12 | $0.15 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 0.9 | 1.0 | 1.0 | 0.9 | · |
| Quick Ratio | 0.7 | 0.7 | 0.6 | 0.6 | · |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $2.31B | $2.05B | $1.87B | $1.76B | · |
Institutional owners (13F) 681 filers · $5.5B total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 82 (-17 vs prior Q) | 56 (-3 vs prior Q) | 215 (+5 vs prior Q) | 214 (+41 vs prior Q) | +23.5M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| Dodge & Cox | $1,398,888,950 | 149,934,507 | 25.61% | Shares |
| FMR LLC | $1,128,848,360 | 120,991,250 | 20.67% | Shares |
| Clearbridge Investments, LLC | $301,752,032 | 32,342,126 | 5.52% | Shares |
| MORGAN STANLEY | $181,578,262 | 19,461,762 | 3.32% | Shares |
| HARRIS ASSOCIATES L P | $157,054,241 | 16,833,252 | 2.88% | Shares |
| Harding Loevner LP | $147,817,757 | 15,414,796 | 2.71% | Shares |
| Nuveen, LLC | $143,055,570 | 15,332,859 | 2.62% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $132,316,353 | 14,181,817 | 2.42% | Shares |
| BANK OF AMERICA CORP /DE/ | $101,231,407 | 10,850,097 | 1.85% | Shares |
| JPMORGAN CHASE & CO | $100,991,616 | 10,824,395 | 1.85% | Shares |
| Point72 Asset Management, L.P. | $86,435,499 | 9,264,255 | 1.58% | Shares |
| RAYMOND JAMES FINANCIAL INC | $67,911,909 | 7,278,875 | 1.24% | Shares |
| NORGES BANK | $66,942,750 | 7,175,000 | 1.23% | Shares |
| Aristotle Capital Management, LLC | $66,153,974 | 7,090,436 | 1.21% | Shares |
| JONES FINANCIAL COMPANIES LLLP | $65,752,882 | 7,116,095 | 1.20% | Shares |
| Douglas Lane & Associates, LLC | $62,439,995 | 6,692,390 | 1.14% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $58,555,920 | 6,276,154 | 1.07% | Shares |
| GOLDMAN SACHS GROUP INC | $50,330,141 | 5,394,442 | 0.92% | Shares |
| WELLS FARGO & COMPANY/MN | $45,944,004 | 4,924,330 | 0.84% | Shares |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | $44,634,617 | 4,783,989 | 0.82% | Shares |
| Bank Julius Baer & Co. Ltd, Zurich | $41,842,598 | 4,481,615 | 0.77% | Shares |
| First Eagle Investment Management, LLC | $39,417,910 | 4,224,856 | 0.72% | Shares |
| BlackRock, Inc. | $37,110,438 | 3,977,539 | 0.68% | Shares |
| NORTHERN TRUST CORP | $36,993,552 | 3,965,011 | 0.68% | Shares |
| CIBC Bancorp USA Inc. | $35,986,757 | 3,856,063 | 0.66% | Shares |
| JANE STREET GROUP, LLC | $34,232,852 | 3,669,116 | 0.63% | Shares |
| ROYAL BANK OF CANADA | $31,587,000 | 3,385,489 | 0.58% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $30,542,528 | 3,273,583 | 0.56% | Shares |
| Bank of New York Mellon Corp | $30,532,830 | 3,272,543 | 0.56% | Shares |
| VAN ECK ASSOCIATES CORP | $28,880,558 | 3,095,451 | 0.53% | Shares |
| WCM INVESTMENT MANAGEMENT, LLC | $24,474,885 | 2,623,246 | 0.45% | Shares |
| STIFEL FINANCIAL CORP | $24,300,563 | 2,604,559 | 0.44% | Shares |
| D. E. Shaw & Co., Inc. | $23,560,984 | 2,525,293 | 0.43% | Shares |
| PRINCIPAL FINANCIAL GROUP INC | $19,823,143 | 2,124,667 | 0.36% | Shares |
| LPL Financial LLC | $18,997,330 | 2,036,156 | 0.35% | Shares |
| Goodman Financial Corp | $16,823,173 | 1,803,127 | 0.31% | Shares |
| Night Squared LP | $16,108,758 | 1,726,555 | 0.29% | Shares |
| CLARK ESTATES INC/NY | $15,861,000 | 1,700,000 | 0.29% | Shares |
| CITADEL ADVISORS LLC | $15,517,022 | 1,663,132 | 0.28% | Shares |
| KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC | $14,574,715 | 1,562,134 | 0.27% | Shares |
| Toroso Investments, LLC | $14,498,832 | 1,434,108 | 0.27% | Shares |
| CITIGROUP INC | $14,065,333 | 1,507,538 | 0.26% | Shares |
| Grantham, Mayo, Van Otterloo & Co. LLC | $13,864,588 | 1,486,022 | 0.25% | Shares |
| FRANKLIN RESOURCES INC | $12,087,393 | 1,295,541 | 0.22% | Shares |
| Cubist Systematic Strategies, LLC | $11,034,974 | 1,230,209 | 0.20% | Shares |
| Quantinno Capital Management LP | $10,740,595 | 1,151,189 | 0.20% | Shares |
| UBS Group AG | $10,487,611 | 1,124,074 | 0.19% | Shares |
| ABC ARBITRAGE SA | $10,349,722 | 1,109,295 | 0.19% | Shares |
| Russell Investments Group, Ltd. | $10,337,943 | 1,108,033 | 0.19% | Shares |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $10,280,447 | 1,101,870 | 0.19% | Shares |
Activists & 5%+ owners 2 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Pfizer Inc. ×5 filings | March 24, 2025 | 0.00% | Amendment | · | SEC |
| Pfizer Inc. (“ Pfizer ” or the “ Reporting Person ”) ×11 filings | Oct. 3, 2024 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF ownership Held by 30 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| EWU · iShares Trust | 1.26% | 10,265,689 SH | Sept. 11, 2026 | Daily |
| EFAV · iShares Trust | 0.63% | 7,499,966 SH | Sept. 11, 2026 | Daily |
| IXJ · iShares Trust | 0.51% | 4,673,180 SH | Sept. 11, 2026 | Daily |
| IDLV · Invesco Exchange-Traded Fund Trust … | 0.45% | 319,679 SH | Oct. 1, 2026 | Daily |
| DMXF · iShares Trust | 0.36% | 751,360 SH | Sept. 11, 2026 | Daily |
| EFV · iShares Trust | 0.36% | 24,941,478 SH | Sept. 11, 2026 | Daily |
| IEV · iShares Trust | 0.28% | 1,028,600 SH | Sept. 11, 2026 | Daily |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.26% | 21,371,662 SH | Aug. 19, 2026 | Daily |
| IEUR · iShares Trust | 0.25% | 5,082,548 SH | Sept. 11, 2026 | Daily |
| PABD · iShares Trust | 0.24% | 176,612 SH | Sept. 11, 2026 | Daily |
| IVLU · iShares Trust | 0.24% | 2,488,919 SH | Sept. 11, 2026 | Daily |
| SPWO · SP Funds Trust | 0.22% | 44,837 NS | July 31, 2026 | N-PORT |
| EFA · iShares Trust | 0.18% | 31,397,031 SH | Sept. 11, 2026 | Daily |
| PXF · Invesco Exchange-Traded Fund Trust … | 0.16% | 1,032,563 SH | Oct. 1, 2026 | Daily |
| IEFA · iShares Trust | 0.16% | 66,967,942 SH | Sept. 11, 2026 | Daily |
| IMFL · Invesco Exchange-Traded Self-Indexe… | 0.15% | 342,307 SH | Oct. 1, 2026 | Daily |
| IDEV · iShares Trust | 0.13% | 9,519,085 SH | Sept. 11, 2026 | Daily |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.12% | 86,891,139 SH | Aug. 19, 2026 | Daily |
| VSGX · VANGUARD WORLD FUND | 0.12% | 1,791,289 SH | Aug. 19, 2026 | Daily |
| ESGD · iShares Trust | 0.11% | 2,830,261 SH | Sept. 11, 2026 | Daily |
| ACWX · iShares Trust | 0.10% | 2,872,444 SH | Sept. 11, 2026 | Daily |
| VEU · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.10% | 20,804,577 SH | Aug. 19, 2026 | Daily |
| IXUS · iShares Trust | 0.09% | 12,141,022 SH | Sept. 11, 2026 | Daily |
| VXUS · VANGUARD STAR FUNDS | 0.09% | 130,756,991 SH | Aug. 19, 2026 | Daily |
| TOK · iShares Trust | 0.05% | 24,876 SH | Sept. 11, 2026 | Daily |
| URTH · iShares, Inc. | 0.04% | 785,701 SH | Sept. 11, 2026 | Daily |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 7,551,644 SH | Aug. 19, 2026 | Daily |
| ACWI · iShares Trust | 0.04% | 2,652,598 SH | Sept. 11, 2026 | Daily |
| CRBN · iShares Trust | 0.03% | 89,587 SH | Sept. 11, 2026 | Daily |
| DFAX · Dimensional ETF Trust | 0.00% | 13,593 NS | July 31, 2026 | N-PORT |
HLN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
5 analysts · 2026-09-29Mean target $11.93 +35.6%
Latest News Recent headlines mentioning this company
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.